Research progress in the role of microRNA-155 in regulation of autophagy and diagnosis and treatment for gastric cancer.
10.11817/j.issn.1672-7347.2019.01.014
- Author:
Gang CHEN
1
,
2
;
Minmin ZHANG
3
;
Yumin LI
1
,
2
Author Information
1. Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou 730030
2. First Department of General Surgery, Second Hospital, Lanzhou University, Lanzhou 730030, China.
3. School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, China.
- Publication Type:Journal Article
- MeSH:
Autophagy;
Cell Line, Tumor;
China;
Gene Expression Regulation, Neoplastic;
Humans;
MicroRNAs;
genetics;
Stomach Neoplasms;
genetics
- From:
Journal of Central South University(Medical Sciences)
2019;44(1):87-91
- CountryChina
- Language:Chinese
-
Abstract:
China is one of the regions with a high incidence of gastric cancer worldwide. Low detection rate and poor curative effect lead to unsatisfied prognosis and low five-year survival rate. Surgery combined with radiotherapy and chemotherapy is the mainstream comprehensive treatment scheme, however, multi-drug resistance may gradually prevail in the chemotherapy process. Chemotherapy, miRNA and autophagy interact with each other, but the mechanism is complex. MiR-155 is abnormally expressed in gastric cancer, which could promote autophagy, inhibit apoptosis, and interact with Helicobacter pylori to induce gastric cancer. Through its regulatory effect on autophagy, miR-155 can be used to treat gastric cancer, improve chemotherapy sensitivity and reverse drug resistance. The high expression of miR-155 in gastric cancer tissues suggests poor prognosis.
